Abstract 862P
Background
Risk group stratification in early-stage endometrial cancer (EC) is mostly based on clinicopathological characteristics, but more recently also on molecular biomarkers. A deeper molecular knowledge of EC is needed to understand the cellular heterogeneity of the disease and to better predict the prognosis and the benefit of treatments. This study aimed to profile selected immune cell markers by using a multiplexed immunfluorescence approach, and to correlate their expression to patient survival.
Methods
A single-institution early-stage EC cohort was prospectively collected between years 2003 and 2015. Patient clinical data were recorded and formalin-fixed and paraffin-embedded tissue samples were used for tissue microarray construction. 7-channel immunofluorescence with quantitative, high-resolution pixel-based image analysis was carried out to measure in-situ tissue marker expression.
Results
314 samples were suitable for the biomarker study, and clinical records from the patients, including follow-up data, were analyzed and correlated with marker expressions. Cox regression survival analysis on marker levels showed a strong association of T-cell markers, CD3, CD4 and CD8, with longer progression-free survival. In contrast, higher expression of T-regulatory cell marker, FOXP3, is related to worse outcome. In multivariate cox regression analysis, the T-cell markers showed independence of patient age, histological grade and subtype, FIGO staging, as well as ESMO risk grouping.
Conclusions
This study shows that immune cell markers of T-helper (CD3, CD4), T-killer (CD3, CD8), and T-regulatory cells (FOXP3) are significantly associated to prognosis in early-stage EC patients. The results warrants for further investigation to study the association of the T-cell markers with regards to effectiveness of different therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hospital Universitario la Paz, IdiPAZ.
Funding
Has not received any funding.
Disclosure
D. Hardisson: Non-remunerated activity/ies, Principal investigator, Molecular Pathology and Therapeutic Targets Lab.: IdiPAZ. A. Redondo: Honoraria (self), speaker and advisory role: PharmaMar; Honoraria (self), speaker and advisory role: Roche; Honoraria (self), speaker and advisory role: AstraZeneca; Honoraria (self), speaker and advisory role: GSK; Honoraria (self), speaker and advisory role: Clovis; Honoraria (self), speaker: Novartis; Honoraria (self), Advisory role: Amgen; Research grant/Funding (institution): Roche; Research grant/Funding (institution): PharmaMar; Research grant/Funding (institution): Eisai; Non-remunerated activity/ies, PI of phase II Cecilia study sponsored by Roche: Roche; Non-remunerated activity/ies, Member of Executive Board and Secretary: GEICO. M. Mendiola: Research grant/Funding (institution), research collaboration: Biocartis; Honoraria (self), speaker: AstraZeneca; Honoraria (self), speaker: Tesaro. All other authors have declared no conflicts of interest.